Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F17%3A00011803" target="_blank" >RIV/75010330:_____/17:00011803 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/16:33160468 RIV/65269705:_____/17:00067268 RIV/00023001:_____/17:00076157 RIV/00216224:14110/17:00098092 RIV/00216208:11120/17:43915997

Výsledek na webu

<a href="http://www.nature.com/tpj/journal/v17/n5/full/tpj201655a.html" target="_blank" >http://www.nature.com/tpj/journal/v17/n5/full/tpj201655a.html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/tpj.2016.55" target="_blank" >10.1038/tpj.2016.55</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216

Popis výsledku v původním jazyce

The Hedgehog pathway is one of the major driver pathways in pancreatic ductal adenocarcinoma. This study investigated prognostic importance of Hedgehog signaling pathway in pancreatic cancer patients who underwent a radical resection. Tumors and adjacent non-neoplastic pancreatic tissues were obtained from 45 patients with histologically verified pancreatic cancer. The effect of experimental taxane chemotherapy on the expression of Hedgehog pathway was evaluated in vivo using a mouse xenograft model prepared using pancreatic cancer cell line Paca-44. Mice were treated by experimental Stony Brook Taxane SB-T-1216. The transcript profile of 34 Hedgehog pathway genes in patients and xenografts was assessed using quantitative PCR. The Hedgehog pathway was strongly overexpressed in pancreatic tumors and upregulation of SHH, IHH, HHAT and PTCH1 was associated with a trend toward decreased patient survival. No association of Hedgehog pathway expression with KRAS mutation status was found in tumors. Sonic hedgehog ligand was overexpressed, but all other downstream genes were downregulated by SB-T-1216 treatment in vivo. Suppression of HH pathway expression in vivo by taxane-based chemotherapy suggests a new mechanism of action for treatment of this aggressive

Název v anglickém jazyce

Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216

Popis výsledku anglicky

The Hedgehog pathway is one of the major driver pathways in pancreatic ductal adenocarcinoma. This study investigated prognostic importance of Hedgehog signaling pathway in pancreatic cancer patients who underwent a radical resection. Tumors and adjacent non-neoplastic pancreatic tissues were obtained from 45 patients with histologically verified pancreatic cancer. The effect of experimental taxane chemotherapy on the expression of Hedgehog pathway was evaluated in vivo using a mouse xenograft model prepared using pancreatic cancer cell line Paca-44. Mice were treated by experimental Stony Brook Taxane SB-T-1216. The transcript profile of 34 Hedgehog pathway genes in patients and xenografts was assessed using quantitative PCR. The Hedgehog pathway was strongly overexpressed in pancreatic tumors and upregulation of SHH, IHH, HHAT and PTCH1 was associated with a trend toward decreased patient survival. No association of Hedgehog pathway expression with KRAS mutation status was found in tumors. Sonic hedgehog ligand was overexpressed, but all other downstream genes were downregulated by SB-T-1216 treatment in vivo. Suppression of HH pathway expression in vivo by taxane-based chemotherapy suggests a new mechanism of action for treatment of this aggressive

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30101 - Human genetics

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacogenomics Journal

ISSN

1470-269X

e-ISSN

1473-1150

Svazek periodika

17

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

452-460

Kód UT WoS článku

000411849200008

EID výsledku v databázi Scopus

—